[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

176

1 the points you raised.
2 Maybe there is this particular drug we
3 have to watch out for, yes. That can then be recorded
4 and collected. It's not zero data collection. It's
5 limited data collection.
6 CO-CHAIRMAN FAUCI: And it's also easy
7 access into the trial, --
8 DR. YUSUF: That's right.
9 CO-CHAIRMAN CARPENTER: Dr. Mazumder, I
10 think you were next.
11 DR. MAZUMDER: Yes. I just wanted to make
12 some comments, I guess, as one of the few non-HIV
13 immunologists here. It seemed to me that a number of
14 the trials, I guess, by necessity of drug
15 availability, if you will, are focusing on certain
16 peptides.
17 Since we really don't know, I think, what
18 the most relevant peptides are, why don't we make,
19 let's say, a concerted effort to look at envelope
20 variants, et cetera, of vaccinia, instead of just
21 having 160 versus 120 versus particular peptides?
22 What if we miss the boat in three years that there are
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, NW.
[phone] WASHINGTON, D.C. 20005 [phone]